Amelot Holdings, Inc. (PINKSHEETS: AMHD) announced that its Corporate attorney, Mr. Andrew Schwab of New York City, has been appointed as Corporate Secretary.

"I am both pleased and honored to have a man of Andrew's high caliber on our team," stated Fred Guarnieri, President and CEO. "Having met with Andrew last week in New York, I can say without any doubt in my mind he will be a major asset to our Company," Mr. Guarnieri further added.

After meeting with Mr. Michael Ajzenman of Madison Stock Transfer in Brooklyn, New York, it was decided that Amelot will continue its relationship as Transfer Agent. Madison Transfer will continue to provide information on the Outstanding and authorized shares of Amelot.

The current Outstanding Common Share balance is 4,309,573,155, none of which is held by the company. The amount of Common Shares Authorized is 4,925,000,000

Any officers wishing to sell stock are limited by the" Dribble Rule" to one percent of the Outstanding Shares per Quarter, or approximately 43 million shares.

"It is important to have liquidity in the market. As many of you are aware there hasn't been any over the past six to eight months. It is my intent to take steps to build investor confidence and interest, thus providing the liquidity that is needed.

"Therefore, I am pleased to announce that through private transactions, I have purchased 404,600,000 shares of Amelot Holdings, Inc.," concluded Fred Guarnieri.

About Amelot Holdings, Inc. (PINKSHEETS: AMHD):

Amelot Holdings, Inc. (http://www.amelotholdings.com), a publicly traded company, is a diversified holding company that has identified Biodiesel as a multi-billion emerging Biofuel market. Amelot plans to have a significant market share in growing low cost feedstocks to supply the growing demand for biodiesel, to reduce energy dependency of fossil fuels, to help reduce the U.S. dependency on foreign oil supplies and reduce the impact of energy on our environment.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing and access funds from our existing financing arrangements that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

Contact: Amelot Holdings, Inc. 1(866)-669-8373 support@amelotholdings.com http://www.amelotholdings.com

HLK Biotech (CE) (USOTC:AMHD)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 HLK Biotech (CE) 차트를 더 보려면 여기를 클릭.
HLK Biotech (CE) (USOTC:AMHD)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 HLK Biotech (CE) 차트를 더 보려면 여기를 클릭.